Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.

Recently developed direct-acting antiviral (DAA) treatments for hepatitis C virus (HCV) have been groundbreaking for their high efficacy across disease genotypes and lack of severe side effects. This study uses a cost-of-illness (COI) approach to estimate the net value conferred by this class of dru...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	David E Bloom, Alexander Khoury, V Srinivasan
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/07d575a975b947019028e918dbf473ae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:07d575a975b947019028e918dbf473ae
record_format	dspace
spelling	oai:doaj.org-article:07d575a975b947019028e918dbf473ae2021-12-02T20:04:58ZEstimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.1932-620310.1371/journal.pone.0252764https://doaj.org/article/07d575a975b947019028e918dbf473ae2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0252764https://doaj.org/toc/1932-6203Recently developed direct-acting antiviral (DAA) treatments for hepatitis C virus (HCV) have been groundbreaking for their high efficacy across disease genotypes and lack of severe side effects. This study uses a cost-of-illness (COI) approach to estimate the net value conferred by this class of drugs using the cost and efficacy of one of these novel drug combinations, sofosbuvir and velpatasvir (SOF/VEL), recently licensed for generic manufacture in India. This study considers COI of lifetime earnings lost by patients and potential secondarily infected individuals due to disability and premature death from HCV infection. Expected net benefits of treatment are substantial for non-cirrhotic (NC) and compensated cirrhotic (CC) patients (ranging from 5,98,003 INR for NC women to 1,05,25,504 INR for CC men). Increased earnings are not sufficient to fully offset cost of treatment for decompensated cirrhotic individuals but treatment may still be justified on the basis of the intrinsic value of health improvements and other treatment benefits.David E BloomAlexander KhouryV SrinivasanPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 7, p e0252764 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q David E Bloom Alexander Khoury V Srinivasan Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
description	Recently developed direct-acting antiviral (DAA) treatments for hepatitis C virus (HCV) have been groundbreaking for their high efficacy across disease genotypes and lack of severe side effects. This study uses a cost-of-illness (COI) approach to estimate the net value conferred by this class of drugs using the cost and efficacy of one of these novel drug combinations, sofosbuvir and velpatasvir (SOF/VEL), recently licensed for generic manufacture in India. This study considers COI of lifetime earnings lost by patients and potential secondarily infected individuals due to disability and premature death from HCV infection. Expected net benefits of treatment are substantial for non-cirrhotic (NC) and compensated cirrhotic (CC) patients (ranging from 5,98,003 INR for NC women to 1,05,25,504 INR for CC men). Increased earnings are not sufficient to fully offset cost of treatment for decompensated cirrhotic individuals but treatment may still be justified on the basis of the intrinsic value of health improvements and other treatment benefits.
format	article
author	David E Bloom Alexander Khoury V Srinivasan
author_facet	David E Bloom Alexander Khoury V Srinivasan
author_sort	David E Bloom
title	Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
title_short	Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
title_full	Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
title_fullStr	Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
title_full_unstemmed	Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
title_sort	estimating the net value of treating hepatitis c virus using sofosbuvir-velpatasvir in india.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/07d575a975b947019028e918dbf473ae
work_keys_str_mv	AT davidebloom estimatingthenetvalueoftreatinghepatitiscvirususingsofosbuvirvelpatasvirinindia AT alexanderkhoury estimatingthenetvalueoftreatinghepatitiscvirususingsofosbuvirvelpatasvirinindia AT vsrinivasan estimatingthenetvalueoftreatinghepatitiscvirususingsofosbuvirvelpatasvirinindia
_version_	1718375523758899200

Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.

Ejemplares similares